Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

3 recruiting5 with results

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

8Total

N/A(5)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07011147Not ApplicableRecruiting

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

Role: collaborator

NCT06449677Phase 3Recruiting

Bionic Pancreas in CFRD

Role: collaborator

NCT06891898Recruiting

The iLet Experience Study

Role: lead

NCT04200313Not ApplicableCompleted

The Insulin-Only Bionic Pancreas Pivotal Trial

Role: collaborator

NCT05168657Not ApplicableCompleted

Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth

Role: collaborator

NCT03258853Not ApplicableCompleted

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

Role: collaborator

NCT02971228Phase 2Completed

Feasibility Trial Testing the Bionic Pancreas With ZP4207

Role: collaborator

NCT04227626Not ApplicableWithdrawn

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Role: collaborator

NCT03840278Phase 2Completed

The Bihormonal iLet Bionic Pancreas Feasibility Study

Role: collaborator

All 9 trials loaded